Finasteride horror stories resurface

Finasteride is a pill that lowers dihydrotestosterone, the hormone that shrinks scalp hair follicles in male pattern hair loss, and U.S. family medicine guidance still lists oral finasteride as a first-line option alongside minoxidil for men. (aafp.org) The reason the drug keeps coming up online is simple: it is taken for a cosmetic problem by many otherwise healthy younger men, and male pattern hair loss affects more than 80 million people in the United States. (aafp.org) The official United States label for Propecia, the 1 milligram finasteride brand for hair loss, says the most common adverse reactions reported in at least 1% of treated patients were decreased libido, erectile dysfunction, and ejaculation disorder. (fda.gov) What turns a routine side-effect warning into a recurring controversy is the claim that some problems do not stop when the pill stops. The United Kingdom medicines regulator said on April 29, 2024 that patients had reported sexual dysfunction persisting after discontinuation, and it rolled out a patient alert card for finasteride packs. (gov.uk) That same United Kingdom review also told prescribers to ask about any history of depression or suicidal thoughts before starting finasteride and to monitor patients for psychiatric as well as sexual side effects. (gov.uk) Europe went further in 2025. The European Medicines Agency said finasteride tablets should carry measures to minimize the risk of suicidal thoughts, and it confirmed suicidal thoughts as a side effect of finasteride tablets after a formal safety review that began on October 3, 2024 and ended with a European Commission decision on August 22, 2025. (ema.europa.eu) The name people use for the worst long-lasting reports is post-finasteride syndrome, which a 2025 review in the International Journal of Impotence Research describes as persistent adverse effects after discontinuation in some former users. That review also says the condition remains heavily debated rather than cleanly settled. (nature.com) A big reason the debate never really ends is that the evidence base is messy. A 2015 JAMA Dermatology meta-analysis found that none of 34 clinical trials had adequate safety reporting, that most safety follow-up lasted 1 year or less, and that the published reports were too limited to firmly establish the drug’s safety profile for hair-loss use. (jamanetwork.com) Newer signal-detection work keeps adding fuel without proving causation on its own. A 2025 PLOS One pharmacovigilance study mined United States Food and Drug Administration adverse-event reports from 2004 through April 2024 to look for reporting patterns tied to finasteride, which is useful for spotting warnings but cannot tell how common an event truly is in all users. (plos.org) That is why the story keeps resurfacing in waves instead of ending with one definitive paper. Regulators in the United Kingdom and Europe now explicitly warn about persistent sexual side effects and psychiatric risks, while researchers still argue over how often these outcomes happen, who is vulnerable, and whether “post-finasteride syndrome” is one condition or several different problems grouped under one name. (gov.uk) (ema.europa.eu) (nature.com)